SageView Advisory Group’s PTC Therapeutics PTCT Stock Holding History

SageView Advisory Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-125	Closed	-$9.5K	–	1962
2025 Q4	$9.5K	Buy	+125	New	+$9.08K	﹤0.01%	1735

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SageView Advisory Group's PTCT Position: Q1 2026 in Review

SageView Advisory Group sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 125 shares — an estimated $9.5K sold.

SageView Advisory Group first reported a position in PTCT in Q4 2025 and held it in 1 quarter. The position peaked at $9.5K in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

SageView Advisory Group reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 125 PTC Therapeutics shares in Q1 2026, an estimated $9.5K.
SageView Advisory Group first reported a position in PTC Therapeutics in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's PTC Therapeutics position peaked at $9.5K in Q4 2025.
352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.